| Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models M Bergstrand, AC Hooker, JE Wallin, MO Karlsson The AAPS journal 13, 143-151, 2011 | 1416 | 2011 |
| Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study AR Mato, NN Shah, W Jurczak, CY Cheah, JM Pagel, JA Woyach, ... The Lancet 397 (10277), 892-901, 2021 | 421 | 2021 |
| Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs C Kloft, J Wallin, A Henningsson, E Chatelut, MO Karlsson Clinical cancer research 12 (18), 5481-5490, 2006 | 117 | 2006 |
| A randomized-controlled phase 2 study of the MET antibody emibetuzumab in combination with erlotinib as first-line treatment for EGFR mutation–positive NSCLC patients G Scagliotti, D Moro-Sibilot, J Kollmeier, A Favaretto, EK Cho, H Grosch, ... Journal of Thoracic Oncology 15 (1), 80-90, 2020 | 71 | 2020 |
| A tool for neutrophil guided dose adaptation in chemotherapy JE Wallin, LE Friberg, MO Karlsson Computer methods and programs in biomedicine 93 (3), 283-291, 2009 | 57 | 2009 |
| First‐in‐human phase I study of merestinib, an oral multikinase inhibitor, in patients with advanced cancer AR He, RB Cohen, CS Denlinger, A Sama, A Birnbaum, J Hwang, T Sato, ... The oncologist 24 (9), e930-e942, 2019 | 53 | 2019 |
| Population pharmacokinetics of tacrolimus in pediatric hematopoietic stem cell transplant recipients: new initial dosage suggestions and a model-based dosage adjustment tool JE Wallin, LE Friberg, A Fasth, CE Staatz Therapeutic drug monitoring 31 (4), 457-466, 2009 | 53 | 2009 |
| Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance JE Wallin, M Bergstrand, HE Wilczek, PS Nydert, MO Karlsson, CE Staatz Therapeutic drug monitoring 33 (6), 663-672, 2011 | 50 | 2011 |
| Model‐based neutrophil‐guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information JE Wallin, LE Friberg, MO Karlsson Basic & clinical pharmacology & toxicology 106 (3), 234-242, 2010 | 48 | 2010 |
| A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+ E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET … DR Camidge, T Moran, I Demedts, H Grosch, JP Di Mercurio, KF Mileham, ... Journal of Clinical Oncology 34 (15_suppl), 9070-9070, 2016 | 34 | 2016 |
| Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer E Elez, A Hendlisz, T Delaunoit, J Sastre, A Cervantes, R Varea, G Chao, ... British Journal of Cancer 114 (4), 372-380, 2016 | 34 | 2016 |
| Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression EK Hansson, JE Wallin, H Lindman, M Sandström, MO Karlsson, ... Cancer chemotherapy and pharmacology 65, 839-848, 2010 | 30 | 2010 |
| A phase I study of an IDO-1 inhibitor (LY3381916) as monotherapy and in combination with an anti-PD-L1 antibody (LY3300054) in patients with advanced cancer N Kotecki, P Vuagnat, BH O’Neil, S Jalal, S Rottey, H Prenen, ... Journal of Immunotherapy 44 (7), 264-275, 2021 | 19 | 2021 |
| A randomized, open-label phase II study evaluating emibetuzumab plus erlotinib and emibetuzumab monotherapy in MET immunohistochemistry positive NSCLC patients with acquired … DR Camidge, T Moran, I Demedts, H Grosch, K Mileham, J Molina, ... Clinical lung cancer 23 (4), 300-310, 2022 | 16 | 2022 |
| Exposure–Response Analysis of Necitumumab Efficacy in Squamous Non‐Small Cell Lung Cancer Patients E Chigutsa, AJ Long, JE Wallin CPT: Pharmacometrics & Systems Pharmacology 6 (8), 560-568, 2017 | 16 | 2017 |
| Population pharmacokinetics of necitumumab in cancer patients A Long, E Chigutsa, J Wallin Clinical Pharmacokinetics 56 (5), 505-514, 2017 | 14 | 2017 |
| Systematic modeling and design evaluation of unperturbed tumor dynamics in xenografts ZP Parra-Guillen, V Mangas-Sanjuan, M Garcia-Cremades, IF Troconiz, ... Journal of Pharmacology and Experimental Therapeutics 366 (1), 96-104, 2018 | 13 | 2018 |
| Dose adaptation based on pharmacometric models J Wallin Acta Universitatis Upsaliensis, 2009 | 11 | 2009 |
| A randomized, controlled, open label phase II study of erlotinib (E) with or without the MET antibody emibetuzumab (Emi) as first-line treatment for EGFRmt non … GV Scagliotti, D Moro-Sibilot, J Kollmeier, AG Favaretto, EK Cho, ... Journal of Clinical Oncology 35 (15_suppl), 9019-9019, 2017 | 10 | 2017 |
| First-in-human phase I study of LY2780301, an oral P70S6K/AKT inhibitor, in patients with refractory solid tumors. E Calvo, KA Benhadji, A Azaro, I Duran, G Argiles, V Boni, U Ohnmacht, ... Journal of Clinical Oncology 30 (15_suppl), 3005-3005, 2012 | 7 | 2012 |
